Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912648850> ?p ?o ?g. }
- W2912648850 endingPage "1719" @default.
- W2912648850 startingPage "1713" @default.
- W2912648850 abstract "Recent data suggest a potential activity and a good tolerability of capecitabine in advanced hepatocellular carcinoma (HCC).To evaluate capecitabine activity and safety in a wide cohort of advanced HCC patients.Retrospective analysis of 143 capecitabine-treated patients (January 2010 to December 2017) in three centers of the Veneto Oncology Network.Capecitabine was administered in second and third line, but also in first line instead of sorafenib in Child-Pugh B patients (70%), compromised clinical conditions (14%) or contraindications to antiangiogenetics (16%). Median overall survival (OS) and time to progression (TTP) were 6.9 and 2.8 months, respectively. There were no differences in OS and TTP between the 32 patients treated with non-metronomic scheme (2000 mg/day for 14 days) and the 111 patients treated with metronomic scheme (1000 mg/day) after correction for prognostic factors at baseline with a propensity score analysis. Capecitabine was more active in patients intolerant to sorafenib than in those progressing during treatment (p = 0.024). At least one adverse event (mainly hematological) was experienced by 73% of patients but discontinuation was necessary only in 11 (8%).Capecitabine can be considered an active and safe option in advanced HCC, especially for patients unfit for other treatments." @default.
- W2912648850 created "2019-02-21" @default.
- W2912648850 creator A5000973050 @default.
- W2912648850 creator A5006309755 @default.
- W2912648850 creator A5011492082 @default.
- W2912648850 creator A5011620415 @default.
- W2912648850 creator A5011805898 @default.
- W2912648850 creator A5041690302 @default.
- W2912648850 creator A5051613962 @default.
- W2912648850 creator A5052747030 @default.
- W2912648850 creator A5060742428 @default.
- W2912648850 creator A5065572516 @default.
- W2912648850 creator A5067890019 @default.
- W2912648850 creator A5084223014 @default.
- W2912648850 creator A5088248706 @default.
- W2912648850 creator A5091093256 @default.
- W2912648850 date "2019-12-01" @default.
- W2912648850 modified "2023-09-27" @default.
- W2912648850 title "Capecitabine in advanced hepatocellular carcinoma: A multicenter experience" @default.
- W2912648850 cites W1828082159 @default.
- W2912648850 cites W1970545762 @default.
- W2912648850 cites W1971837077 @default.
- W2912648850 cites W1988975349 @default.
- W2912648850 cites W2000307707 @default.
- W2912648850 cites W2004969691 @default.
- W2912648850 cites W2016170717 @default.
- W2912648850 cites W2020215421 @default.
- W2912648850 cites W2022662750 @default.
- W2912648850 cites W2024450952 @default.
- W2912648850 cites W2029029081 @default.
- W2912648850 cites W2030395635 @default.
- W2912648850 cites W2032995236 @default.
- W2912648850 cites W2044970916 @default.
- W2912648850 cites W2046000826 @default.
- W2912648850 cites W2051684210 @default.
- W2912648850 cites W2059294866 @default.
- W2912648850 cites W2066204710 @default.
- W2912648850 cites W2070080743 @default.
- W2912648850 cites W2079586464 @default.
- W2912648850 cites W2090806526 @default.
- W2912648850 cites W2108381668 @default.
- W2912648850 cites W2109202667 @default.
- W2912648850 cites W2118184318 @default.
- W2912648850 cites W2119242310 @default.
- W2912648850 cites W2120967735 @default.
- W2912648850 cites W2128965737 @default.
- W2912648850 cites W2137194656 @default.
- W2912648850 cites W2146324931 @default.
- W2912648850 cites W2153280781 @default.
- W2912648850 cites W2155163959 @default.
- W2912648850 cites W2163486683 @default.
- W2912648850 cites W2171541660 @default.
- W2912648850 cites W2234354671 @default.
- W2912648850 cites W2277004004 @default.
- W2912648850 cites W2281335839 @default.
- W2912648850 cites W2480981995 @default.
- W2912648850 cites W2502891277 @default.
- W2912648850 cites W2560499218 @default.
- W2912648850 cites W2606367731 @default.
- W2912648850 cites W2761031851 @default.
- W2912648850 cites W2770527972 @default.
- W2912648850 cites W2771874080 @default.
- W2912648850 cites W2787358630 @default.
- W2912648850 cites W2795488377 @default.
- W2912648850 cites W2805592007 @default.
- W2912648850 cites W2809889937 @default.
- W2912648850 cites W2810381975 @default.
- W2912648850 cites W2908573150 @default.
- W2912648850 cites W4245784696 @default.
- W2912648850 doi "https://doi.org/10.1016/j.dld.2019.06.015" @default.
- W2912648850 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31320302" @default.
- W2912648850 hasPublicationYear "2019" @default.
- W2912648850 type Work @default.
- W2912648850 sameAs 2912648850 @default.
- W2912648850 citedByCount "17" @default.
- W2912648850 countsByYear W29126488502020 @default.
- W2912648850 countsByYear W29126488502021 @default.
- W2912648850 countsByYear W29126488502022 @default.
- W2912648850 countsByYear W29126488502023 @default.
- W2912648850 crossrefType "journal-article" @default.
- W2912648850 hasAuthorship W2912648850A5000973050 @default.
- W2912648850 hasAuthorship W2912648850A5006309755 @default.
- W2912648850 hasAuthorship W2912648850A5011492082 @default.
- W2912648850 hasAuthorship W2912648850A5011620415 @default.
- W2912648850 hasAuthorship W2912648850A5011805898 @default.
- W2912648850 hasAuthorship W2912648850A5041690302 @default.
- W2912648850 hasAuthorship W2912648850A5051613962 @default.
- W2912648850 hasAuthorship W2912648850A5052747030 @default.
- W2912648850 hasAuthorship W2912648850A5060742428 @default.
- W2912648850 hasAuthorship W2912648850A5065572516 @default.
- W2912648850 hasAuthorship W2912648850A5067890019 @default.
- W2912648850 hasAuthorship W2912648850A5084223014 @default.
- W2912648850 hasAuthorship W2912648850A5088248706 @default.
- W2912648850 hasAuthorship W2912648850A5091093256 @default.
- W2912648850 hasConcept C121608353 @default.
- W2912648850 hasConcept C126322002 @default.
- W2912648850 hasConcept C143998085 @default.
- W2912648850 hasConcept C167135981 @default.